|Analyst / Firm||Company||Price||Rating||Price Target||Upside/Downside||Date|
JOHNSON & JOHNSONJNJ
2 days ago
#234 out of 3729 analysts
57%55 out of 97
Risk vs Reward
Wuensch bumped her price target on Johnson & Johnson down by 2.4%.
"Higher inflation, slowing growth, and rising interest rates" are all contributing to "contracting market multiples," the analyst said.
"We don't know how deep the de-rating will go," Wuensch continued, or "where the medical technology sector will shake out."
The answer to that question will depend upon the interplay between "the recovery in elective surgical procedures and macro headwinds," Wuensch explained.
"When is the right time to catch a falling knife?" the analyst asked rhetorically. "If recent history is any indication, the answer could be soon."
a day ago